CN120076827A - 用于治疗造血干细胞移植物相关血栓性微血管病(hsct-tma)的抗c5抗体的补充剂量和施用 - Google Patents

用于治疗造血干细胞移植物相关血栓性微血管病(hsct-tma)的抗c5抗体的补充剂量和施用 Download PDF

Info

Publication number
CN120076827A
CN120076827A CN202380071841.9A CN202380071841A CN120076827A CN 120076827 A CN120076827 A CN 120076827A CN 202380071841 A CN202380071841 A CN 202380071841A CN 120076827 A CN120076827 A CN 120076827A
Authority
CN
China
Prior art keywords
dose
patients weighing
patient
antibody
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380071841.9A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·奥尔蒂斯
乔纳森·蒙特莱昂
晓枫·王·里尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CN120076827A publication Critical patent/CN120076827A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202380071841.9A 2022-09-06 2023-09-01 用于治疗造血干细胞移植物相关血栓性微血管病(hsct-tma)的抗c5抗体的补充剂量和施用 Pending CN120076827A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263404061P 2022-09-06 2022-09-06
US63/404,061 2022-09-06
US202363440984P 2023-01-25 2023-01-25
US63/440,984 2023-01-25
PCT/US2023/031836 WO2024054408A1 (en) 2022-09-06 2023-09-01 Supplemental dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)

Publications (1)

Publication Number Publication Date
CN120076827A true CN120076827A (zh) 2025-05-30

Family

ID=88192212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380071841.9A Pending CN120076827A (zh) 2022-09-06 2023-09-01 用于治疗造血干细胞移植物相关血栓性微血管病(hsct-tma)的抗c5抗体的补充剂量和施用

Country Status (9)

Country Link
EP (1) EP4583910A1 (enExample)
JP (1) JP2025529317A (enExample)
KR (1) KR20250060282A (enExample)
CN (1) CN120076827A (enExample)
AU (1) AU2023338677A1 (enExample)
CA (1) CA3266974A1 (enExample)
IL (1) IL319413A (enExample)
TW (1) TW202426048A (enExample)
WO (1) WO2024054408A1 (enExample)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
ES2796078T3 (es) * 2013-09-16 2020-11-25 Childrens Hospital Med Ct Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
WO2016200627A1 (en) * 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
TW201718014A (zh) * 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP2023503776A (ja) * 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
JP7821160B2 (ja) 2020-08-13 2026-02-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
CA3173016A1 (en) * 2021-01-22 2022-07-28 Gin-Fu CHEN Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody

Also Published As

Publication number Publication date
JP2025529317A (ja) 2025-09-04
TW202426048A (zh) 2024-07-01
CA3266974A1 (en) 2024-03-14
WO2024054408A1 (en) 2024-03-14
AU2023338677A1 (en) 2025-03-27
IL319413A (en) 2025-05-01
EP4583910A1 (en) 2025-07-16
KR20250060282A (ko) 2025-05-07

Similar Documents

Publication Publication Date Title
JP7227312B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
US20250051428A1 (en) Antibodies to amyloid beta
JP6634158B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用
TWI660972B (zh) 抗ｍｃａｍ抗體及相關使用方法
JP7520725B2 (ja) 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
JP6105146B2 (ja) Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体
JP2024015045A (ja) 発作性夜間ヘモグロビン尿症（ｐｎｈ）の処置のための抗ｃ５抗体の皮下投薬及び投与
JP7461875B2 (ja) 病気の症状の治療又は予防に使用するための抗アドレノメデュリン（ａｄｍ）バインダー
JP2023533030A (ja) 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与
JP2024504366A (ja) 抗ｃ５抗体を使用して補体媒介血栓性微小血管障害症を治療する方法
JP2024503724A (ja) 免疫調節抗体およびその使用
US12286469B2 (en) Humanized antibodies binding to amyloid-beta (A-beta)
KR20230047179A (ko) 조혈 줄기세포 이식-연관 혈전성 미세혈관병증(hsct-tma)을 치료하기 위한 항-c5 항체의 복용량 및 투여
JP2023526051A (ja) 発作性夜間ヘモグロビン尿症の処置のための補体ｄ因子阻害剤の単独又は抗ｃ５抗体との組み合わせでの使用
JP2025529317A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を治療するための抗ｃ５抗体の補足的投薬及び投与
WO2019014768A1 (en) ANTI-BETA-AMYLOID ANTIBODY
US20250289877A1 (en) Antibodies to Amyloid Beta
EP3814376A1 (en) Transthyretin antibodies and uses thereof
WO2025235419A1 (en) Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
JP2023547505A (ja) ＳＡＲＳ－ＣｏＶ－２ヌクレオカプシド抗体
HK40017344B (en) Antibodies to amyloid beta
HK40017344A (en) Antibodies to amyloid beta
BR112015020174B1 (pt) Anticorpo que liga gro-alfa, gro-beta, gro-gama, ena-78, gcp-2, nap-2 e il-8 humanos, seu uso e seu processo de produção, e molécula de dna

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination